Approval · Notice of Compliance 26534 · 2021
PREGABALIN: Notice of Compliance 26534
Issued August 27, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26534
- Date
- August 27, 2021
- Company
- Alembic Pharmaceuticals LimitedVadodara, Gujarat, India
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the product monograph
- Canadian reference product
- LYRICA (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PREGABALIN | Not yet assigned | — |
Medicinal ingredients
- PREGABALIN 25 MG per CAP
- PREGABALIN 50 MG per CAP
- PREGABALIN 75 MG per CAP
- PREGABALIN 100 MG per CAP
- PREGABALIN 150 MG per CAP
- PREGABALIN 200 MG per CAP
- PREGABALIN 225 MG per CAP
- PREGABALIN 300 MG per CAP